13-Cis-retinoic acid and Interferon alplia-2a in patients with advanced esophageal cancer: A phase II trial

Investigational New Drugs

Volumn 14, Issue 4, 1996, Pages 391-394

  Slabber, Coenraad F ^a   Falkson, Geoffrey ^a,b   Burger, Wilma ^a   Schoeman, Lizette ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b Faculty of Education   (South Africa)

Author keywords

Advanced esophageal cancer; Cis retinoic acid; Interferon

Indexed keywords

ALPHA2A INTERFERON; RETINOIC ACID;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEILITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONSTIPATION; DRUG FORMULATION; DRY SKIN; ESOPHAGUS CANCER; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; HYPOTENSION; LEUKOPENIA; MALAISE; MALE; MYALGIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 0030455513     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Sitas F, Terblanche M, Madhoo J: National Cancer Registry of South Africa, 1996
2. Mannel A, Murry W: Oesophageal cancer in South Africa. A review of 1926 cases. Cancer 64:2604-2608, 1989
3. Ezdinli EZ, Gelber R, Desai DV, Falkson G, Moertel CG, Hahn RG: Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience. Cancer 46:2149-2153, 1980
4. Falkson G: Methyl-GAG (NSC 32946) in the treatment of oesophagus cancer. Cancer Chemother Rep 55:209-212, 1971
5. Davis S, Shanmugathasa M, Kessler W: cis-Dichlorodiammineplatinum (II) in the treatment of esophageal carcinoma. Cancer Treat Rep 64:709-711, 1980
6. Ansell SM, Alberts AS, Falkson G: Ifosfamide in advanced carcinoma of the esophagus : a phase II trial with severe toxicity. Am J Clin Oncol 12:205-207, 1989
7. Alberts AS, Falkson G, Badat M, Terblanche APS, Schmid EU: Trimetrexate in advanced carcinoma of the esophagus. Invest New Drugs 6:319-321, 1986
8. Falkson G, Ryan LM, Haller DG: Phase II trial for the evaluation of trimetrexate in patients with inoperable squamous carcinoma of the esophagus. Am J Clin Oncol 15:433-435, 1992
9. Engstrom PF, Lavin PT, Klaassen DJ: Phase II evaluation of mitomycin and cisplatin in advanced esophageal carcinoma. Cancer Treat Rep 67:713-715, 1983
10. Kolaric K, Maricic Z, Dujmovic I, Roth A: Therapy of advanced esophageal cancer with bleomycin, irradiation and combination of bleomycin with irradiation. Tumori 62:255-262, 1976
11. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG: Therapy for gastrointestinal cancer with nitrosoureas alone and in drug combination. Cancer Treat Rep 60:729-732, 1976
12. Kelsen DP, Bains M, Cvitkovic E, Golby R: Vindesine in the treatment of esophageal carcinoma: a phase II study. Cancer Treat Rep 63:2019-2021, 1979
13. Coonley CJ, Bains M, Heelan M, Dukeman M, Kelsen DP: Phase II study of etoposide in the treatment of esophageal carcinoma. Cancer Treat Rep 67:397-398, 1983
14. Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326:1593-1598, 1992
15. Alberts AS, Burger W, Greef F, Schoeman L, Friediger D, Nel J, Steyn E, Schmid EU, Falkson G: Severe complications of 5-fluorouracil and cisplatin with concomitant radiotherapy in inoperable non-metastatic squamous cell oesophageal cancer after intubation-early termination of a prospective randomised trial. Eur J Cancer 28A: 1005-1006, 1992
16. Lippman SM, Parkinson DR, Itri LM, Weber RS, Schantz SP, Ota DM, Schusterman MA, Krakoff IW, Gutterman JU, Hong WK: 13-cis-retinoic acid and interferon alfa-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84:235-241, 1992
17. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrueno F, Paredes-Cassilas P, Hong WK, Holdener E, Krakoff IH: 13-cis-retinoic acid plus interferon alfa-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 84:241-245, 1992
18. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982